T-cell receptor recognizing insulin peptide–MHC complexes (TCR-Ins-MHC)

The T-cell receptor (TCR) recognizing insulin peptide–MHC complexes is a pivotal molecular target in the pathogenesis of Type 1 Diabetes (T1D). This receptor complex, located on the surface of autoreactive T-lymphocytes, specifically identifies insulin-derived peptides—most notably the insulin B-chain residues 9-23—when they are presented by Major Histocompatibility Complex (MHC) molecules such as HLA-DQ8 or HLA-DR4 (Nakayama et al., 2005; Michels et al., 2011). This recognition event serves as the primary trigger for the autoimmune destruction of pancreatic beta cells, leading to absolute insulin deficiency. Because this interaction is highly specific to the disease-causing T-cell population, it represents an ideal target for precision immunotherapies aimed at restoring immune tolerance without broad immunosuppression (Pathiraja et al., 2015). Current therapeutic strategies include the use of soluble peptide-MHC complexes to desensitize T-cells, DNA vaccines encoding proinsulin to induce regulatory T-cells, and peptide-based therapies designed to halt the progression of T1D in newly diagnosed patients (Yu et al., 2000; ClinicalTrials.gov).

Other names

Insulin-specific T-cell receptorInsulin-reactive T-cell receptorTCR-insulin-HLA complexAutoreactive insulin-specific TCR

Induction of antigen-specific immune tolerance, deletion of autoreactive T-cells, or modulation of T-cell activation through competitive binding or regulatory T-cell induction.